Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Origene Technologies
company
About
OriGene Technologies is a research tool company that provides a commercial collection of full-length human cDNAs.
- 501 - 1000
Highlights
Details
- Last Funding Type
- Grant
- Industries
- Biotechnology,Genetics,Medical Device,Pharmaceutical
- Founded date
- Jan 1, 1996
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs. It strives to fulfill its mission of supplying everything a researcher needs for gene-based research. Through licensing and selling research materials including genes, proteins, and research tools, it enables critical biological research.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$16M
Origene Technologies has raised a total of
$16M
in funding over 2 rounds. Their latest funding was raised on
Mar 24, 2010 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 24, 2010 | Series B | $16M | 2 |
Zero2IPO Capital
|
— | Detail |
| Sep 23, 2004 | Grant | — | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
2
3
Origene Technologies is funded by 3 investors.
Zero2IPO Capital
and SBI & TH Venture Capital Enterprise
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Zero2IPO Capital
|
Yes | Series B |
|
|
Yes | Series B |
National Institutes of Health
|
— | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
